Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd

Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd

Introduction: Rabies is a 100% fatal disease with significant disease burden in Asia and Africa but preventable with vaccines and immunoglobulins. There are very few WHO prequalified cell culture derived rabies vaccines available globally for use in humans. We have developed a new purified vero cell...

Bibliografiset tiedot
Päätekijät:	Prasad S. Kulkarni, Ashish Sahai, Bhagwat Gunale, Rajeev M Dhere
Aineistotyyppi:	Artikkeli
Kieli:	English
Julkaistu:	Taylor & Francis Group 2017-04-01
Sarja:	Expert Review of Vaccines
Aiheet:	rabivax-s rabies purified vero cell rabies vaccine safety immunogenicity
Linkit:	http://dx.doi.org/10.1080/14760584.2017.1294068

Samankaltaisia teoksia

Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children
Tekijä: Piyada Angsuwatcharakon, et al.
Julkaistu: (2018-02-01)

Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes
Tekijä: Jia Li, et al.
Julkaistu: (2024-12-01)

Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine
Tekijä: D.J. Briggs, et al.

Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above
Tekijä: Jing Wang, et al.
Julkaistu: (2017-01-01)

DETERMINATION OF THE RABIES VIRUS-INFECTED VERO LINE CELL PORTION BY FLOW CYTOMETRY
Tekijä: A. L. Kravtsov, et al.
Julkaistu: (2019-08-01)

A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens
Tekijä: Hua-Kun Lv, et al.
Julkaistu: (2025-02-01)

Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: a systematic literature review and meta-analysis
Tekijä: Scott Preiss, et al.
Julkaistu: (2018-06-01)

Study on immune persistence of the CTN-1V strain rabies vaccine in humans
Tekijä: Lidong Wang, et al.
Julkaistu: (2024-03-01)

Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects
Tekijä: Nianmin Shi, et al.
Julkaistu: (2017-06-01)

Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination
Tekijä: Zheng-Gang Zhu, et al.
Julkaistu: (2018-11-01)

Evaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine
Tekijä: Jia Li, et al.
Julkaistu: (2024-12-01)

Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
Tekijä: Pornthep Chanthavanich, et al.
Julkaistu: (2018-04-01)

A Randomized, Double-Blind, Controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of a Lyophilized Human Rabies Vaccine (Vero Cells) in Healthy Participants Aged 10–60 Years Following Essen and Zagreb Vaccination Procedures
Tekijä: Xiaohong Wu, et al.
Julkaistu: (2023-08-01)

Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context
Tekijä: Gagandeep Kang, et al.
Julkaistu: (2023-07-01)

Infection and Prevention of Rabies Viruses
Tekijä: Shiu-Jau Chen, et al.
Julkaistu: (2025-02-01)

Development of mRNA rabies vaccines
Tekijä: Zixin Fang, et al.
Julkaistu: (2024-12-01)

Purified Vero Cell Rabies Vaccine (PVRV, Verorab<sup>®</sup>): A Systematic Review of Intradermal Use Between 1985 and 2019
Tekijä: Thomas Moulenat, et al.
Julkaistu: (2020-03-01)

Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10–60 years in China
Tekijä: Zhenzhen Liang, et al.
Julkaistu: (2024-11-01)

Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial
Tekijä: Lei Zhang, et al.
Julkaistu: (2021-08-01)

A STUDY OF THE ULTRASTRUCTURE OF THE SURFACE OF THE TRANSPLANTABLE LINE VERO CELLS INFECTED WITH THE RABIES VIRUS (RABV, LISSAVIRUS, RHABDOVIRIDAE)
Tekijä: S. V. Generalov, et al.
Julkaistu: (2017-10-01)

Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial
Tekijä: Xingyu Zhou, et al.
Julkaistu: (2019-04-01)

Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial
Tekijä: Heng Shen, et al.
Julkaistu: (2021-02-01)

Efficacy of Purified Vero Cell Rabies Vaccine (PVRV) under the Zagreb Regimen in Iran
Tekijä: Pooneh Rahimi, et al.
Julkaistu: (2014-08-01)

Rabies and rabies immunobiological preparations: vaccinations Pasteur to the contemporary biotechnology
Tekijä: E. G. Abramova, et al.
Julkaistu: (2019-11-01)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
Tekijä: Xiaoyuan Huang, et al.
Julkaistu: (2023-01-01)

Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified
Tekijä: Hanna K, et al.
Julkaistu: (2018-06-01)

Retrospective study of rabies epidemiology in Ukraine (1950-2019)
Tekijä: I. F. Makovska, et al.
Julkaistu: (2020-03-01)

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against reindeer rabies
Tekijä: Irina Matveeva, et al.
Julkaistu: (2022-09-01)

Management of rabies
Tekijä: J. Weyer, et al.
Julkaistu: (2019-07-01)

The Formation of the Eastern Africa Rabies Network: A Sub-Regional Approach to Rabies Elimination
Tekijä: Emily G Pieracci, et al.
Julkaistu: (2017-07-01)

Atypical rabies encephalitis in a six-year-old boy: clinical, radiological, and laboratory findings
Tekijä: Sunil Karande, et al.
Julkaistu: (2015-07-01)

A case of human rabies in the Urban Area of Ribeirão Preto, SP, Brazil
Tekijä: SILVA Jorgete M., et al.
Julkaistu: (1997-01-01)

A case of human survival of rabies, South Africa
Tekijä: Jacqueline Weyer, et al.
Julkaistu: (2016-07-01)

Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
Tekijä: Weerawan Hattasingh, et al.
Julkaistu: (2022-01-01)

Amino Acid Mutation in Position 349 of Glycoprotein Affect the Pathogenicity of Rabies Virus
Tekijä: Jun Luo, et al.
Julkaistu: (2020-04-01)

Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study
Tekijä: Gadey Sampath, et al.
Julkaistu: (2017-07-01)

Factors related to vaccines for both patients exposed with rabies and dogs
Tekijä: Lam Quy Ngo, et al.
Julkaistu: (2022-03-01)

Factors related to vaccines for both patients exposed with rabies and dogs
Tekijä: Lam Quy Ngo, et al.
Julkaistu: (2022-03-01)

Letter to the editor: Safety and immunogenicity of a novel recombinant rabies vaccine
Tekijä: Anurag Agarwal, et al.
Julkaistu: (2022-11-01)

MANAJEMEN INFEKSI RABIES BERISIKO TINGGI: STUDI KASUS TANPA SERUM ANTI-RABIES
Tekijä: Mahdika Ambarwaty, et al.
Julkaistu: (2023-12-01)